"Revolutionary Dual-Action Immunotherapy Unleashes Potent Anti-Tumor Response"

A new molecule, ABBV-CLS-484, developed by TIDE, AbbVie, and Calico Life Sciences, shows promise in cancer immunotherapy by enhancing tumor susceptibility and boosting immune cell potency. The small molecule, currently in clinical trials, works through two different mechanisms to slow tumor growth and increase survival in lab animals. By inhibiting specific proteins, the molecule makes tumors more sensitive to immune attack and enhances the activity of immune cells. This dual-action approach is unique compared to other cancer immunotherapies and may explain why the molecule is effective on its own. The molecule's discovery and development were made possible through a collaboration between academia and industry.